BA – Carson-Newman College, Jefferson City, Tennessee
MD – Joan C. Edwards School of Medicine, Marshall University, Huntington, West Virginia
Internship/Residency – University of Tennessee, LeBonheur Children’s Hospital
Fellowship (Pediatric Hematology/Oncology) – St. Jude Children’s Research Hospital
- Bleeding disorders
- Sickle Cell Disease
Mesleh Shayeb A, Smeltzer MP, Kaste SC, Brown A, Estepp JH, Nottage KA. Vaso-occlusive crisis as a predictor of symptomatic avascular necrosis in children with sickle cell disease. Pediatr Blood Cancer Sept. 5;e27435, 2018.
Hankins JS, Estepp JH, Hodges JR, Villavicencio MA, Robison LL, Weiss MJ, Kang G, Schreiber JE, Porter JS, Kaste SC, Saving KL, Bryant PC, Deyo JE, Nottage KA, King AA, Brandow AM, Lebensburger JD, Adesina O, Chou ST, Zemel BS, Smeltzer MP, Wang WC, Gurney JG. Sickle Cell Clinical Research and Intervention Program (SCCRIP): A lifespan cohort study for sickle cell disease progression from the pediatric stage into adulthood. Pediatr Blood Cancer May 24;e27228, 2018.
Estepp JH. Voxelotor (GBT440), a first-in-class hemoglobin oxygen-affinity modulator, has promising and reassuring preclinical and clinical data. Am J Hematol 93(3):326-329, 2018.
Cancio MI, Aygun B, Chui DHK, Rothman JA, Scott JP, Estepp JH, Hankins JS. The clinical severity of hemoglobin S/Black (A γδβ)0 -thalassemia. Pediatr Blood Cancer Apr 28; 64:11, 2017.
Gammal RS, Crews KR, Haidar CE, Hoffman JM, Baker DK, Barker PJ, Estepp JH, Pei D, Broeckel U, Wang W, Weiss MJ, Relling MV, Hankins J. Pharmacogenetics for safe codeine use in sickle cell disease. Pediatrics 138(1), 2016.
Estepp JH, Melloni C, Thornburg CD, Wiczling P, Rogers Z, Rothman JA, Green NS, Liem R, Brandow AM, Crary SE, Howard TH, Morris MH, Lewandowski A, Garg U, Jusko WJ, Neville KA. Pharmacokinetics and bioequivalence of a liquid formulation of hydroxyurea in children with sickle cell anemia. J Clin Pharmacol 56(3):298-306, 2015.
Estepp JH, Winter B, Johnson M, Smeltzer MP, Howard SC, Hankins JS. Improved hydroxyurea effect with the use of text messaging in children with sickle cell anemia. Pediatr Blood Cancer 61(11):2031-36, 2014.
Estepp JH, Smeltzer MP, Wang WC, Hoehn ME, Hankins JS, Aygun B. Protection from sickle cell retinopathy is associated with elevated HbF levels and hydroxycarbamide use in children. Br J Haematol 161(3):402-405, 2013.
Estepp JH, Smeltzer M, Reiss UM. The impact of quality and duration of enoxaparin therapy on recurrent venous thrombosis in children. Pediatr Blood Cancer 59(1):105-109, 2012.
Last update: October 2018